Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review

[1] Stupp R(2009)Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459-466

[2] Hegi ME(2021)Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma Neuro-Oncol Adv 22 1073-1113

[3] Mason WP(2020)Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions Neuro-Oncol 18 170-186

[4] Balasubramanian A(2021)EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Nat Rev Clin Oncol 17 98-110

[5] Gunjur A(2010)Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 131 803-820

[6] Hafeez U(2016)The 2016 World Health Organization classification of tumors of the central nervous system: a summary Acta Neuropathol (Berl) 14 979-993

[7] Wen PY(2012)In vivo models of primary brain tumors: pitfalls and perspectives Neuro-Oncol 133 263-282

[8] Weller M(2017)Glioma: experimental models and reality Acta Neuropathol (Berl) 16 509-520

[9] Lee EQ(2019)Challenges to curing primary brain tumours Nat Rev Clin Oncol 8 67-78

[10] Weller M(2006)Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma Neuro-Oncol 10 71-81

[1] Stupp R(2009)Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459-466

[2] Hegi ME(2021)Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma Neuro-Oncol Adv 22 1073-1113

[3] Mason WP(2020)Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions Neuro-Oncol 18 170-186

[4] Balasubramanian A(2021)EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Nat Rev Clin Oncol 17 98-110

[5] Gunjur A(2010)Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 131 803-820

[6] Hafeez U(2016)The 2016 World Health Organization classification of tumors of the central nervous system: a summary Acta Neuropathol (Berl) 14 979-993

[7] Wen PY(2012)In vivo models of primary brain tumors: pitfalls and perspectives Neuro-Oncol 133 263-282

[8] Weller M(2017)Glioma: experimental models and reality Acta Neuropathol (Berl) 16 509-520

[9] Lee EQ(2019)Challenges to curing primary brain tumours Nat Rev Clin Oncol 8 67-78

[10] Weller M(2006)Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma Neuro-Oncol 10 71-81